| Unaudited Condensed Consolidated Statement of Financial Position at March 31, 2023 and December 31, 2022 | PAGE 1 | | --- | --- | | Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the | | | Three Month Periods ended March 31, 2023 and 2022 | 2 | | Unaudited Condensed Consolidated Statement of Changes in Equity for the Three Month Periods Ended March | | | 31, 2023 and 2022 | 3 | | Unaudited Condensed Consolidated Statement of Cash Flows for the Three Month P ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Exhibit 99.1 ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event LEIDEN, Netherlands & CAMBRIDGE, Mass., March 29, 2023 – ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced initial pipeline programs focused on diseases that originate in the liver. ProQR will host a virtual R&D event today, during wh ...

Table of Contents Exhibit 99.1 The notes are an integral part of these condensed consolidated financial statements. Table of Contents PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements | PAGE | | | --- | --- | | Unaudited Condensed Consolidated Statement of Financial Position at September 30, 2022 and | 1 | | December 31, 2021 | | | Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income | 2 | | for the Three and Nine Month Periods ende ...

| Unaudited Condensed Consolidated Statement of Financial Position at June 30, 2022 and December | 1 | | --- | --- | | 31, 2021 | | | Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income | 2 | | for the Three and Six Month Periods ended June 30, 2022 and 2021 | | | Unaudited Condensed Consolidated Statement of Changes in Equity for the Six Month Periods | 3 | | Ended June 30, 2022 and 2021 | | | Unaudited Condensed Consolidated Statement of Cash Flows for the Three and ...

Table of Contents Exhibit 99.1 PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements | PAGE | | | --- | --- | | Unaudited Condensed Consolidated Statement of Financial Position at March 31, 2022 and December 31, | 1 | | 2021 | | | Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the | 2 | | Three Month Periods ended March 31, 2022 and 2021 | | | Unaudited Condensed Consolidated Statement of Changes in Equity for the Three Month ...

CREATING MEDICINES for patients in need Nasdaq: PRQR Date: April 2022 Forward looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including but not limited to, statements regarding our updated strategic plans and intended benefits thereof, future operations, future preclinical and clinical trial plans and related timing of trials and results, regul ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ◻ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ◻ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

ProQR® TOP-LINE RESULTS: PHASE 1/2 TRIAL OF SEPOFARSEN IN LCA10 PATIENTS Conference call October 10, 2019 Forward looking statements This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. ...